NASDAQ NMS - GLOBAL MARKET · SNGX
0.00% · $0.0000 · Vol 342.8K
Market closed · last close 4:00 PM ET · price as of 18:13:28 ET
Soligenix Inc

Soligenix Inc

Biotechnology
$0.3700
Card
Relationship Map

Follow $SNGX

One email when a member of Congress discloses a trade in it, with the official filing receipt linked.

Free. No account. Unsubscribe in one click.

Follow $SNGX by email

Veridion Score

BETALOW CONF · 4 of 6 factors measuredMethodology
Earnings absence reason unknown · Sentiment absence reason unknown
SNGX
Soligenix Inc
Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Middle range

Highest qualified requires a score of at least 75 and high confidence, including full factor coverage. Upper range can hold a higher score with lower confidence.

Composite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.

59/ 100
Veridion Score
Middle range · LOW confidence · 4 of 6 factors measured
Sovereign · $25/mo
See why this score moved.
  • · Factor breakdown with raw signals
  • · Day-over-day delta + driver
  • · Factor coverage readout
  • · Valuation · hype · market flow
  • · Pro Chart event markers
  • · Score history + alerts
Confidence: LOW · 4 of 6 factors measured · Mon Sep 21 · market closed · Markets closed · resumes Tue 9:30 ET
Veridion Score History · 90D
Loading score history
AI Analysis
Sovereign

Why is SNGX moving today?

Sovereign unlock connects news, insider activity, analyst moves, and live price action.
Loading SNGX catalysts
About Soligenix Inc
PHARMACEUTICAL PREPARATIONS
Listed since
1994
Employees
14
Country
US

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely: The Public Health Solutions business segment includes development programs for RiVax, a ricin toxin vaccine candidate, GX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease and various vaccine programs, including a program targeting filoviruses and CiVax; and The Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte, utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL).

Key statistics

Reported fields plus Veridion-computed history. Unsourced tiles are omitted.

Open
$0.3800
Day high
$0.3810
Day low
$0.3650
Previous close
$0.3700
52W high
$2.33
-84.12% from high
52W low
$0.2801
4% of range
Market cap
$8.1M
EPS
$-1.8000
Beta
1.99
Shares out
21.8M
Volume
342.8K
1.41× rel vol
Avg volume
243.3K
VWAP
$0.3699
Price history computed in-house
1W
+2.75%
1M
-7.73%
3M
-5.37%
1Y
-84.12%
YTD
-72.39%
SMA 50 $0.3755 · below
SMA 200 $0.8382 · below
52W position 4%

SNGX overview

Loading financial statements
Loading SNGX Form 4 filings
Public disclosures

Congress activity in SNGX

No receipt-qualified Congressional disclosure is present for SNGX in the cached public ledger.

Federal contracts

SNGX contract awards, year to date.

Public federal awards linked to this ticker.

Not disclosed
Refresh interval: 12hSource: Federal contract awards
No federal contracts on file for SNGX in this window.
Lobbying spend

SNGX lobbying filings, year to date.

Registered lobbying filings matched to Soligenix Inc.

Not disclosed
Refresh interval: 12hSource: LDA disclosure filings
No lobbying filings on file for SNGX in this window.
Loading news for SNGX
Analyst ratings
Sovereign unlock shows live analyst consensus for SNGX.
Options
Sovereign unlock shows live options positioning for SNGX.
Weekly Veridion brief

Rating changes, public disclosure activity, methodology notes, and product updates. One email per week. No advertising list resale.